Yanmei Xu

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook et al. · The Lancet Oncology · 2012 · 558 citations

Medicine, Pharmacokinetics, Pharmacology +11

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

Kevin B. Kim, Richard Kefford, Anna C. Pavlick et al. · Journal of Clinical Oncology · 2012 · 477 citations · Full text

Medicine, Oncology, Pharmacology +17

Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer

Xu Chen, Yanmei Xu, Xingyun Liao et al. · Tumor Biology · 2016 · 78 citations · Full text

Medicine, Bioinformatics, Oncology +15

Radiosensitizing effects of miR‐18a‐5p on lung cancer stem‐like cells via downregulating both <scp>ATM</scp> and <scp>HIF</scp>‐1α

Xu Chen, Lei Wu, Dezhi Li et al. · Cancer Medicine · 2018 · 66 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer

Luping Zhang, Yanmei Xu, Shen Jie et al. · Radiation Oncology · 2016 · 29 citations · Full text

Medicine, Immunology, Oncology +17